Periyanayagi Muruganantham, Arthi Mohankumar, Rajakumari Murugesan
Intermediate uveitis is a form of uveitis localised to the vitreous and peripheral retina. Primary sites of inflammation include the vitreous of which other such entities as pars planitis, posterior cyclitis and hyalitis are encompassed. The aim of this study was to describe the demographic features and clinical outcomes in patients with intermediate uveitis.
MATERIALS AND METHODS
39 patients were included in our study for the institution of antituberculous therapy. After obtaining informed consent, they underwent a complete ophthalmological examination. All patients of presumed tuberculous aetiology underwent Mantoux skin testing, ESR, chest x-ray and QuantiFERON gold TB testing when necessary. All patients were started on antituberculous therapy along with oral prednisolone. Reduction in vitritis by two grades or improvement in BCVA by two lines was considered as response to therapy along with reduction in recurrence of inflammation. Patients were reviewed periodically.
The mean age of the study population was 35.4 years. The patients presented with symptoms like defective vision and the commonest sign was vitritis. The commonest complication encountered in our study was cystoid macular oedema. The recurrences were found to be lower when compared to the episodes before the institution of antituberculous therapy and was found to be statistically significant (p<0.05).
In patients with intermediate uveitis, detailed evaluation should be carried out to rule out tuberculous aetiology. Prompt institution of antituberculous therapy may reduce complications and improve the visual outcome.